Antengene
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · China · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Soho Plaza 1065 W Zhongshan Road Suites ...Phone Number
+86 1050951066Website
www.antengene.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Antengene
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on innovative first-in-class/best-in-class therapeutic medicines for cancer and other life-threatening diseases. Driven by its vision of "Treating Patients Beyond Borders", Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since initiating operations in 2017, Antengene has obtained 23 investigational new drug (IND) approvals in the US and in Asia, submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) in China, South Korea, Singapore and Australia approved. Leveraging partnerships as well as in-house drug discovery, Antengene has built a broad and expanding pipeline of 15 clinical and pre-clinical assets. Antengene has global rights on 10 programs and Asia Pacific rights, including the Greater China region, on 5 programRead more
Antengene Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Antengene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Antengene had a recent Job posting/layoffs
Antengene, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Antengene has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Antengene recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Antengene
Check out if Antengene is spiking on competitors!
Funding: Get notified immidiatlly once Antengene has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Antengene launches new products
Recommended Actions
Find VP level buyers at Antengene
Find more new buyers
Company Profile Activity
Activity Insights
Antengene is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Antengene is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Antengene.
Antengene financials insights
Gather financial insights about Antengene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$21M
2019
Series B
$120M
2020
Series C
$97M
Antengene Tech Stack
A closer look at the technologies used by Antengene
See more technologies
Most Recent Scoops
Promotion
Executive Move
Executive Moves, Promotion
New Hire
Executive Move
Antengene has announced that Amily Zhang has joined the organization as Chief Medical Officer.
Lateral Move
Executive Move
Antengene has announced that Kevin Lynch has stepped down from the role of Chief Medical Officer. Lynch will remain with the organization as Senior Advisor.
Facilities Relocation / Expansion
Earnings
Sales
Antengene News & Media
Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
SHANGHAI and HONG KONG, June 7, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
SHANGHAI and HONG KONG, June 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that it has presented the first preclinical data on ATG-207, α masked and TGFβRIII-biased CD3-TGF-β bifunctional fusion proAntengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
SHANGHAI and HONG KONG, May 27, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Antengene
Sign Up For FreeTo access detailed company insights
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on innovative first-in-class/best-in-class therapeutic medicines for cancer and other life-threatening diseases. Driven by its vision of "Treating Patients Beyond Borders", Antengene aims to provide the most a... Read More
